Johnson & Johnson Innovative Medicine

Name

Johnson & Johnson Innovative Medicine

Legal name

Johnson & Johnson Innovative Medicine

Website

https://jnj.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Oncology pharmaceuticals
• Bispecific antibodies
• CAR-T cell therapy
• Immunology biologics
• Targeted cancer therapy

Headquarters

HQ city

Beerse

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Revenue generated from selling proprietary pharmaceutical products including bispecific antibodies, CAR-T therapies, and targeted oncology treatments
2. Licensing and partnerships: Revenue from strategic partnerships including technology transfers and licensing agreements such as the LigaChem Biosciences TROP2-targeted ADC deal worth 2.25 trillion won

Distribution channels1 record

Marketing channels3 records

Core offering

Johnson & Johnson Innovative Medicine develops, manufactures, and commercializes prescription pharmaceutical products, with a focus on innovative therapeutics across oncology, immunology, neuroscience, and rare diseases. Its commercial portfolio includes bispecific antibodies (RYBREVANT, TECVAYLI, TALVEY), a next-generation EGFR TKI (LAZCLUZE), the CAR-T cell therapy CARVYKTI for multiple myeloma, and the IL-23 inhibitor TREMFYA for plaque psoriasis. The division also advances a pipeline of targeted therapies, including mTORC1 inhibitors for autosomal dominant polycystic kidney disease, distributed via specialty pharmacies and hospital systems globally.

Product overview

Johnson & Johnson Innovative Medicine operates as a pharmaceutical company with a diversified portfolio of approved therapeutics and pipeline candidates. The company offers multiple bispecific antibodies including RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) for EGFR-mutated NSCLC, TECVAYLI and TALVEY for multiple myeloma, and TREMFYA for autoimmune conditions. The CAR-T cell therapy CARVYKTI addresses hematologic malignancies, while acquired programs like AT-20494 expand the pipeline into rare diseases.

Differentiator

Problem solved

Functional benefit

Brands

• RYBREVANT (amivantamab): EGFR/MET bispecific antibody approved for EGFR-mutated advanced NSCLC in combination with LAZCLUZE
• TREMFYA (guselkumab)
• TECVAYLI (teclistamab)
• TALVEY (talquetamab)
• CARVYKTI (ciltacabtagene autoleucel)
• LAZCLUZE (lazertinib)

Products and services

• RYBREVANT (amivantamab) A bispecific antibody targeting EGFR and MET receptors, approved for treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), including in combination with LAZCLUZE.
• LAZCLUZE (lazertinib) A next-generation tyrosine kinase inhibitor (TKI) targeting EGFR mutations, approved for use in combination with RYBREVANT as first-line treatment for EGFR-mutated advanced NSCLC.
• TECVAYLI (teclistamab) A bispecific antibody targeting BCMA (B-cell maturation antigen) for the treatment of relapsed or refractory multiple myeloma.
• TALVEY (talquetamab) A bispecific antibody targeting GPRC5D for the treatment of relapsed or refractory multiple myeloma.
• CARVYKTI (ciltacabtagene autoleucel) A CAR-T cell therapy (ciltacabtagene autoleucel) for the treatment of relapsed or refractory multiple myeloma, demonstrating durable treatment-free remissions in the CARTITUDE-4 study.
• TREMFYA (guselkumab) A monoclonal antibody targeting IL-23 for the treatment of plaque psoriasis in adults and pediatric patients, approved for pediatric plaque psoriasis in September 2025.
• AT-20494 An mTORC1 inhibitor acquired through the Anakuria Therapeutics acquisition, targeting autosomal dominant polycystic kidney disease.

Quantifiable outcome

• 80.5% 30-month progression-free survival rate with CARVYKTI in standard-risk multiple myeloma patients
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Anakuria TherapeuticscoreStrategic or Co-development Partner · 2 February 2022Janssen Pharmaceuticals acquired Anakuria Therapeutics, a company formed by Navitor Pharmaceuticals to develop mTORC1 inhibitors. Transaction facilitated by Johnson & Johnson Innovation. Lead program AT-20494 targets autosomal dominant polycystic kidney disease.
• UltromicscoreTechnology or Integration · 1 January 2021Collaboration to develop AI platform EchoGo Amyloidosis using artificial intelligence to detect cardiac amyloidosis from routine echocardiograms. Platform granted FDA Breakthrough Device Status.
• MeiraGTx HoldingscoreStrategic or Co-development PartnerStrategic collaboration with MeiraGTx advancing gene therapy programs. MeiraGTx is a clinical-stage genetic medicine company with pipeline including Parkinson's disease and achromatopsia treatments.
• LigaChem BiosciencescoreStrategic or Co-development Partner$2.25 trillion won (~$1.7 billion) partnership for TROP2-targeted ADC LCB84 export to Johnson & Johnson Innovative Medicine. Major deal facilitated by Korea Drug Development Fund.
• ZymeworksminorStrategic or Co-development PartnerZymeworks achieved $25 million milestone from Johnson & Johnson. Progressing clinical programs including ZW191 and ZW251 with encouraging clinical data.
• Trial LibraryminorGTM or Marketing PartnerPartnership with Trial Library, an AI-enabled platform expanding access to clinical trials as a care option. Trial Library has network of 320+ clinics and 1,500+ providers.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bristol-Myers Squibb: A major oncology-focused pharma with overlapping multiple-myeloma (Empliciti) and solid-tumor franchises, and with active bispecific and CAR-T programs that compete head-to-head with Johnson & Johnson Innovative Medicine.
• Merck & Co. A leading oncology franchise built around Keytruda with active bispecific and ADC programs, directly competing with Johnson & Johnson Innovative Medicine in NSCLC and other solid-tumor indications.
• Roche: Operates a major biologics and bispecific oncology platform (Genentech) and competes in lung cancer, hematology, and immunology segments with overlapping therapeutic targets.
• AstraZeneca: A diversified oncology-led biopharma with EGFR franchise (Tagrisso) and ADC/bispecific programs that compete against RYBREVANT in NSCLC and other J&J oncology assets.
• Novartis: A major cell-therapy and targeted-oncology player with Kymriah (the first approved CAR-T) and radioligand therapies that compete in the same hematology and solid-tumor markets as CARVYKTI.
• AbbVie: An immunology-and-oncology-led biopharma with deep hematology and bispecific programs (including Elahere and BCMA-directed assets) that overlap with J&J's multiple-myeloma and immunology franchises.
• Gilead Sciences (Kite): Owns Kite, a leading CAR-T franchise (Yescarta, Tecartus) and a major direct competitor to Johnson & Johnson Innovative Medicine's CARVYKTI in B-cell and multiple-myeloma cell therapy.
• Eli Lilly: A diversified biopharma expanding aggressively in oncology, immunology (Taltz), and bispecifics, competing with TREMFYA in autoimmune disease and with J&J's bispecific pipeline in oncology.
• Amgen: A leading biologics manufacturer with a bispecific program (e.g., Blincyto) and oncology portfolio that competes with Johnson & Johnson Innovative Medicine's bispecific and hematology assets.

Broad incumbents

• Pfizer: A diversified large-cap pharma with broad oncology, immunology, and cell-therapy assets, competing across multiple Johnson & Johnson Innovative Medicine therapeutic areas including lung cancer and hematology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/JNJInnovMed
• Facebookfacebook.com/JNJInnovativeMedicine
• LinkedInlinkedin.com/company/jnjinnovativemedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson Innovative Medicine